Selective cyclooxygenase-2 (COX-2) inhibitors: The COXIBs; [Selektif Siklo-oksijenaz-2 (COX-2) Inhibitörleri: KOKSIB'ler]

Simple item page
dc.contributor.authorTikiz C.
dc.date.accessioned2024-07-22T08:24:38Z
dc.date.available2024-07-22T08:24:38Z
dc.date.issued2004
dc.description.abstractNonsteroidal anti-inflammatory drugs are the most widely used medications in the world. These agents are especially preferred to treat arthritis, headache and menstrual pain because of their analgesic and anti-inflammatory properties. During their long-term use they increase the risk of gastric erosion, peptic ulcus and bleeding by inhibiting the synthesis of prostaglandins which protect the gastric mucosa. The major limitation of these drugs is gastrointestinal (GI) toxicity occurring in 2% to 4% of patients every year. The inhibition of cyclooxygenase-1 (COX- 1) is the main factor in GI toxicity which necessiated further research on selective cyclooxygenase-2 (COX-2) inhibitors. In 1990, a novel cyclooxygenase protein was identified in monocytes which was stimulated by interleukin. After this observation, next year a different gene which was quite similar to COX-1 had been identified. Identification of this gene responsible from the synthesis of COX-2 rekindled the affords of the pharmacuetical industry to produce a safer analgesic and anti-inflammatory agent by selective inhibition of COX-2. Celecoxib and rofecoxib are the first two agents introduced for clinical use in 1999. They were prescribed more than 100 million for the 12 month period ending in July 2000 in the United States. In this review, the available data about the types, structural properties, mechanism of action and side effects of selective COX-2 inhibitors were summarized.
dc.identifier.issn13020234
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/20062
dc.language.isoTurkish
dc.subjectacetylsalicylic acid
dc.subjectcelecoxib
dc.subjectcyclooxygenase 1
dc.subjectcyclooxygenase 1 inhibitor
dc.subjectcyclooxygenase 2 inhibitor
dc.subjectdiclofenac
dc.subjectetodolac
dc.subjectetoricoxib
dc.subjectibuprofen
dc.subjectindometacin
dc.subjectmeloxicam
dc.subjectnabumetone
dc.subjectnaproxen
dc.subjectnimesulide
dc.subjectnonsteroid antiinflammatory agent
dc.subjectparacetamol
dc.subjectparecoxib
dc.subjectrofecoxib
dc.subjectsulfonamide
dc.subjectvaldecoxib
dc.subjectanalgesia
dc.subjectantiinflammatory activity
dc.subjectarthritis
dc.subjectclinical trial
dc.subjectdigestive system perforation
dc.subjectdrug choice
dc.subjectdrug determination
dc.subjectdrug indication
dc.subjectdrug mechanism
dc.subjectdrug preference
dc.subjectdrug safety
dc.subjectdrug selectivity
dc.subjectdrug structure
dc.subjectdysmenorrhea
dc.subjectenzyme inhibition
dc.subjectgastrointestinal hemorrhage
dc.subjectgastrointestinal toxicity
dc.subjectgene identification
dc.subjectheadache
dc.subjecthuman
dc.subjectlong term care
dc.subjectosteoarthritis
dc.subjectpeptic ulcer
dc.subjectprescription
dc.subjectprostaglandin synthesis inhibition
dc.subjectreview
dc.subjectside effect
dc.subjectstomach erosion
dc.subjectstructure analysis
dc.titleSelective cyclooxygenase-2 (COX-2) inhibitors: The COXIBs; [Selektif Siklo-oksijenaz-2 (COX-2) Inhibitörleri: KOKSIB'ler]
dc.typeReview

Files

Collections

Scopus Koleksiyonu